Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Andrizzi

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Leukemia & Lymphoma|May 1, 1996
Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 casesG Meloni, M Vignetti, C Andrizzi, et al.
Stem Cells (Dayton, Ohio)|July 1, 1993
Interleukin 2 treatment in acute myelogenous leukemiaF Mandelli, M Vignetti, S Tosti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1996
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experienceM Vignetti, E Orsini, M C Petti, et al.
Bone Marrow Transplantation|October 6, 1997
Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitorsC Carlo-Stella, A Tabilio, E Regazzi, et al.
Haematologica|May 1, 1997
Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cellsC Carlo-Stella, E Regazzi, C Andrizzi, et al.
Bone Marrow Transplantation|January 1, 1991
ABMT for children AML: Italian experience. GITMO-AIEOP GroupsG Meloni, M Vignetti, C Andrizzi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Leukemia & Lymphoma|May 1, 1996
Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 casesG Meloni, M Vignetti, C Andrizzi, et al.
Stem Cells (Dayton, Ohio)|July 1, 1993
Interleukin 2 treatment in acute myelogenous leukemiaF Mandelli, M Vignetti, S Tosti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1996
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experienceM Vignetti, E Orsini, M C Petti, et al.
Bone Marrow Transplantation|October 6, 1997
Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitorsC Carlo-Stella, A Tabilio, E Regazzi, et al.
Haematologica|May 1, 1997
Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cellsC Carlo-Stella, E Regazzi, C Andrizzi, et al.
Bone Marrow Transplantation|January 1, 1991
ABMT for children AML: Italian experience. GITMO-AIEOP GroupsG Meloni, M Vignetti, C Andrizzi, et al.
Pageof 1